Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Trial of AK117 (Anti-CD47) in Patients With Higher-risk Myelodysplastic Syndrome

Next Previous
X
Search
Trial Profile

A Phase I/II Trial of AK117 (Anti-CD47) in Patients With Higher-risk Myelodysplastic Syndrome

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Ligufalimab (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Akeso Biopharma

    • Most Recent Events

    • 15 Dec 2023 According to an Akeso Biopharma media release, company received FDA clearance for the Investigational New Drug (IND) application for AK117 in combination with azacitidine for the treatment of patients with newly diagnosed higher-risk MDS
    • 15 Dec 2023 According to an Akeso Biopharma Media Release, company published results from this trial at the 65th American Society of Hematology (ASH) Annual Meeting.
    • 15 Dec 2023 Results presented in an Akeso Biopharma media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top